SL
VKTX icon

Salomon & Ludwin’s Viking Therapeutics VKTX Stock Holding History

Salomon & Ludwin’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.7K Hold
152
– – ﹤0.01% 1786
2026
Q1 		$5.29K Hold
152
– – ﹤0.01% 1751
2025
Q4 		$4.88K Hold
152
– – ﹤0.01% 1790
2025
Q3 		$4.52K Buy
+152
New +$4.54K ﹤0.01% 1758

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Salomon & Ludwin's VKTX Position: Q2 2026 in Review

Salomon & Ludwin held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 152 shares worth $5.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1786.

Salomon & Ludwin first reported a position in VKTX in Q3 2025 and has held it in 4 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Salomon & Ludwin held 152 shares of Viking Therapeutics worth $5.7K as of Q2 2026.
  • Salomon & Ludwin left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #1786 holding.
  • Salomon & Ludwin first reported a position in Viking Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.